simendan has been researched along with Body Weight in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Abdelrahman, AM; Al Salam, S; Al Suleimani, Y; Ali, BH; Ashique, M; Manoj, P | 1 |
Akhtar, MS; Dhyani, N; Hassan, MQ; Ismail, MV; Najmi, AK; Pillai, KK | 1 |
Antila, S; Eha, J; Kivikko, M; Lehtonen, L; Pentikäinen, PJ | 1 |
1 trial(s) available for simendan and Body Weight
Article | Year |
---|---|
Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Topics: Aged; Analysis of Variance; Blood Pressure; Body Weight; Calcium Channel Blockers; Cardiotonic Agents; Chronic Disease; Electrocardiography; Erythrocyte Indices; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan | 2002 |
2 other study(ies) available for simendan and Body Weight
Article | Year |
---|---|
Effect of levosimendan, an inodilator, on streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cardiotonic Agents; Cytokines; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Hyperglycemia; Kidney; Male; Oxidative Stress; Polyuria; Rats; Rats, Sprague-Dawley; Simendan | 2020 |
Levosimendan reduces myocardial damage and improves cardiodynamics in streptozotocin induced diabetic cardiomyopathy via SERCA2a/NCX1 pathway.
Topics: Animals; Body Weight; Cardiomyopathies; Cardiotonic Agents; Diabetes Mellitus, Experimental; Heart; Hemodynamics; Hydrazones; Male; Natriuretic Peptide, Brain; Nitric Oxide; Pyridazines; Rats; Rats, Wistar; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Calcium Exchanger; Streptozocin; Transforming Growth Factor beta; Troponin I | 2016 |